血管紧张素转换酶抑制剂与孤立性重型创伤性脑损伤患者死亡率增加的相关性
这项回顾性队列研究纳入2010年1月至2014年12月间在一家学术性一级创伤中心收治的年龄≥40岁、孤立性创伤性脑损伤(头部简明损伤定级≥3且胸部、腹部、四肢简明损伤定级≤2)患者600例,且均未使用β受体阻滞剂。伤前使用ACEI者死亡率为10%(10/96),未使用者为5%(25/504),差异有统计学意义(P=0.04);多因素逐步logistic回归显示ACEI组死亡风险增加三倍(P<0.001),高于损伤严重度评分≥16所对应的两倍风险。在纳入伤前使用β受体阻滞剂患者的第二次分析(n=98)中,ACEI组死亡风险仅增加两倍(P=0.05)。作者认为伤前使用ACEI与孤立性创伤性脑损伤患者死亡率增加相关,而β受体阻滞剂可减弱此效应。
要点
- 孤立性创伤性脑损伤患者伤前使用ACEI者住院死亡率为10%(10/96),未使用者为5%(25/504),P=0.04。
- 多因素分析中ACEI组死亡风险增加三倍(P<0.001),高于损伤严重度评分≥16对应的两倍风险。
- 纳入伤前使用β受体阻滞剂患者后,ACEI组多因素分析死亡风险仅增加两倍(P=0.05)。
- 作者认为伤前ACEI暴露与孤立性创伤性脑损伤死亡率增加相关,β受体阻滞剂可能提供保护性获益。
适用人群与场景
- 年龄≥40岁、因孤立性创伤性脑损伤入住学术性一级创伤中心的患者,纳入时间为2010年1月至2014年12月。
- 孤立性创伤性脑损伤定义为头部简明损伤定级≥3,且胸部、腹部、四肢简明损伤定级≤2。
- 初始分析排除同时使用β受体阻滞剂的患者;第二次分析纳入伤前使用β受体阻滞剂的患者(n=98)。
诊断标准与关键阈值
- 孤立性创伤性脑损伤:头部简明损伤定级≥3,胸部、腹部、四肢简明损伤定级≤2。
- 伤前用药通过病历审查确定。
研究设计与关键结果
- 回顾性队列研究,纳入600例未使用β受体阻滞剂的孤立性创伤性脑损伤患者,主要终点为住院死亡率。
- 伤前使用ACEI组死亡率为10%(10/96),未使用ACEI组为5%(25/504),P=0.04。
- 多因素逐步logistic回归显示ACEI组死亡风险增加三倍(P<0.001),高于损伤严重度评分≥16对应的两倍死亡风险。
- 第二次分析纳入伤前使用β受体阻滞剂的患者(n=98),ACEI组多因素分析死亡风险仅增加两倍(P=0.05)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为伤前ACEI暴露与孤立性创伤性脑损伤患者死亡率增加相关。
- 作者认为β受体阻滞剂可能减弱ACEI相关的死亡率增加,提示该类药物可能提供保护性获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Traumatic brain injury (TBI) is associated with one-third of all deaths from trauma. Preinjury exposure to cardiovascular drugs may affect TBI outcomes. Angiotensin-converting enzyme inhibitors (ACEIs) exacerbate brain cell damage and worsen functional outcomes in the laboratory setting. β-blockers (BBs), however, appear to be associated with reduced mortality among patients with isolated TBI.
OBJECTIVE: Examine the association between preinjury ACEI and BB use and clinical outcome among patients with isolated TBI.
METHODS: A retrospective cohort study of patients age ≥ 40 years admitted to an academic level 1 trauma center with isolated TBI between January 2010 and December 2014 was performed. Isolated TBI was defined as a head Abbreviated Injury Scale (AIS) score ≥ 3, with chest, abdomen, and extremity AIS scores ≤ 2. Preinjury medication use was determined through chart review. All patients with concurrent BB use were initially excluded. In-hospital mortality was the primary measured outcome.
RESULTS: Over the 5-year study period, 600 patients were identified with isolated TBI who were naive to BB use. There was significantly higher mortality (P = .04) among patients who received ACEI before injury (10 of 96; 10%) than among those who did not (25 of 504; 5%). A multivariate stepwise logistic regression analysis revealed a threefold increased risk of mortality in the ACEI cohort (P < .001), which was even greater than the twofold increased risk of mortality associated with an Injury Severity Score ≥ 16. A second analysis that included patients who received preinjury BBs (n = 98) demonstrated slightly reduced mortality in the ACEI cohort with only a twofold increased risk in multivariate analysis (P = .05).
CONCLUSIONS: Preinjury exposure to ACEIs is associated with an increase in mortality among patients with isolated TBI. This effect is ameliorated in patients who receive BBs, which provides evidence that this class of medications may provide a protective benefit.
参考来源
- Catapano JS, Chapman AJ, Dull M, et al. Association of Angiotensin-Converting Enzyme Inhibitors with Increased Mortality Among Patients with Isolated Severe Traumatic Brain Injury. Neurocrit Care. 2019. PMID: 31187434. doi:10.1007/s12028-019-00755-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。